Modeling For Pharmaceuticals .pdf
Original filename: Modeling For Pharmaceuticals.pdf
This PDF 1.5 document has been generated by Microsoft® Office Word 2007, and has been sent on pdf-archive.com on 17/07/2015 at 11:53, from IP address 182.64.x.x.
The current document download page has been viewed 296 times.
File size: 368 KB (3 pages).
Privacy: public file
Download original PDF file
Modeling For Pharmaceuticals
Technomics Research is a consulting service dedicated to the demonstration of the value of
healthcare technologies in support of coverage, reimbursement, and rapid dissemination.
Technomics' health economists and statisticians use cutting-edge modeling and analytic
techniques to create a variety of media to make your case to regulatory bodies, healthcare
payers, purchasers, and providers.
Technomics Research is a consulting service dedicated to the
demonstration of the value of healthcare technologies in
support of coverage, reimbursement, and rapid dissemination.
Technomics' health economists use cutting-edge modeling and
analytic techniques to create a variety of media to make your
case to healthcare payers, purchasers, and providers.
Meet The Team
Melissa Martinson, MS PhD
Dr. Martinson is a health services researcher and biostatistician, and is
Adjunct Associate Professor in the Division of Health Policy and
Management, School of Public Health, University of Minnesota.
Dr. Martinson's commercial experience includes 20 years of clinical
trials, health economics and outcomes studies in both medical device
and pharmaceutical companies.
Teresa Nelson, MS
Teresa Nelson, MS is a biostatistician with over 15 years experience in the
medical device industry in the areas of statistics and health economics. She
has extensive experience in study design strategy, analysis of data,
interpretation of results and writing of reports for government regulatory
bodies, commercial insurers and for publication in journals. She has
worked on projects in all phases of research from feasibility or pre-market to those supporting
market approval and post-market and outcomes studies.
Director, IT and Analytics
Noel Martinson, BS
Noel Martinson is a software developer and data analyst with over 20
years’ experience in manipulating large datasets for analysis and
modeling in complex software systems. Before joining Technomics, he
was responsible for software development and validation in mid-sized
Manya Harsch, MS
Manya Harsch, MS is a biostatistician at Technomics Research, LLC with
over 10 years of experience in the medical device industry. She has
worked at major medical device companies with emphasis on cardiac
and urological devices. She is an enthusiastic, experienced critical
thinker with strong statistical background and solid biological training
and understanding of clinical trials.
Health Economics & Statistical Analysis
Technomics Research Services
Technomics Research provides several types of
analyses and related services that are aimed at
demonstrating the value of your healthcare
product. Frequently, new technologies are
approved for market based on improved clinical
results, but are also more expensive. In these cases,
payers and purchasers often need to understand
how cost-effective your product is compared to its
competitors. Or you may have a technology that
reduces cost without sacrificing the clinical benefit.
In this case, you are likely to need a costminimization analysis. If the product is capital
equipment, the purchaser may need an ROI (return
on investment) analysis. Technomics Research can
help you assess what kind of analysis would be
Economic modeling and analyses: cost-effectiveness, cost-minimization, cost-utility, ROI,
budget impact, and others
Outcomes research, study design and analysis
Disease management program evaluation
Clinical research, study design and analysis
Statistical design and analysis (Bayesian and Frequentist)
Examples of Case Studies
Company Made Medical Device That Decreased The Rate Of Infections in Traumatic Wounds
A company made a medical device that, in randomized clinical
trial, decreased the rate of infections in traumatic wounds
treated in the emergency department. The hospital buyers
objected to the cost of the device. Dr. Martinson developed a
pro forma which demonstrated that in uninsured patients, the
device was cost saving because it prevented additional
hospital losses that would have occurred if infections had
developed in these patients. The company reported that it
enjoyed good adoption in hospitals serving populations with
high uninsurance rates.
New Drug Developed To Treat Diabetic Wounds
A pharmaceutical start-up developed a new drug to treat
infected diabetic wounds and wanted to understand how the
product could be rationally priced. Dr. Martinson developed a
value-based pricing model which demonstrated that the drug
would be valued at a relative high price because it would avert
wound complications that would have cost more money than
Therapy for Incontinence Equally Effective And Less Costly Than Competitive Therapies
A medical device manufacturer developed a therapy for
incontinence that was equally effective and less costly
compared to a competitive therapy. In spite of this, insurers
were sometimes reluctant to cover it. Dr. Martinson developed
a Markov model showing the cost-effectiveness of the
company's device compared to the competition. A paper from
this study in under publication review, which the company
believes will be received favorably by insurers.